Astellas Advances Antibody R&D Agenda With Agensys Purchase Worth Up To $537 Million
Privately held Agensys brings a proprietary portfolio of cancer targets, a preclinical pipeline of mAbs and small proteins, and antibody manufacturing capabilities.